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Abstract
Background: Type 2 Diabetes Mellitus (T2DM) is a chronic, progressive incurable disease affecting over 23.6
million people in the US. This disease involves the deterioration of β-cell function, which causes
hyperglycemia. Early diagnosis and treatment of diabetes is essential and helps prevent long-term medical
complications such as neuropathy, nephropathy and retinopathy. Treatment begins with diet, exercise and
weight loss and then progresses to oral hypoglycemic agents (OHAs), combination OHAs, and finally to
insulin therapy. Initial treatment with insulin may improve β-cell function, reduce glucotoxicity and increase
insulin secretion when compared to the usual course of OHA treatment.
Hypothesis: What effect does insulin treatment have on β-cell function in newly diagnosed T2DM patients?
Methods: Exhaustive search of available medical literature from 1998 to present, for studies regarding newly
diagnosed T2DM patients, treated with insulin as compared to metformin and/or a sulfonylurea, which
included the evaluation of β-cell function. The four studies reviewed evaluated β-cell function by measuring
fasting c-peptide, insulin and proinsulin levels, post-prandial c-peptide levels, HOMA B, HOMA IR or
proinsulin-to-insulin ratios.
Results: Newly diagnosed T2DM patients treated with insulin had increased c-peptide, insulin, HOMA B and
post-prandial c-peptide levels, and decreased proinsulin, HOMA IR and proinsulin-to-insulin ratios, all of
which indicate improved β-cell function. This improvement was measured over durations of 6, 12, and 24
months, and after that point a decline was seen. Treatment with OHAs showed a similar pattern, however,
insulin treatment showed greater improvement which lasted for longer periods of time.
Conclusion: Optimal improvement in β-cell function of T2DM patients is seen with early, intensive, short-
term treatment with insulin vs. metformin or a sulfonylurea. Increase in β-cell function helps to improve
metabolic control, increase insulin secretion, increase acute insulin response to glucose and decrease PI/IRI
ratios. Due to the progressive nature of T2DM, this improvement in β-cell function deteriorates gradually
with time.
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Abstract   
 
Background:  Type 2 Diabetes Mellitus (T2DM) is a chronic, progressive incurable 
disease affecting over 23.6 million people in the US.  This disease involves the 
deterioration of β-cell function, which causes hyperglycemia.  Early diagnosis and 
treatment of diabetes is essential and helps prevent long-term medical complications such 
as neuropathy, nephropathy and retinopathy.  Treatment begins with diet, exercise and 
weight loss and then progresses to oral hypoglycemic agents (OHAs), combination 
OHAs, and finally to insulin therapy.  Initial treatment with insulin may improve β-cell 
function, reduce glucotoxicity and increase insulin secretion when compared to the usual 
course of OHA treatment. 
 
Hypothesis:  What effect does insulin treatment have on β-cell function in newly  
diagnosed T2DM patients? 
 
Methods:  Exhaustive search of available medical literature from 1998 to present, for 
studies regarding newly diagnosed T2DM patients, treated with insulin as compared to 
metformin and/or a sulfonylurea, which included the evaluation of β-cell function.  The 
four studies reviewed evaluated β-cell function by measuring fasting c-peptide, insulin 
and proinsulin levels, post-prandial c-peptide levels, HOMA B, HOMA IR or proinsulin-
to-insulin ratios. 
 
Results: Newly diagnosed T2DM patients treated with insulin had increased c-peptide, 
insulin, HOMA B and post-prandial c-peptide levels, and decreased proinsulin, HOMA 
IR and proinsulin-to-insulin ratios, all of which indicate improved β-cell function.  This 
improvement was measured over durations of 6, 12, and 24 months, and after that point a 
decline was seen.  Treatment with OHAs showed a similar pattern, however, insulin 
treatment showed greater improvement which lasted for longer periods of time. 
 
Conclusion:  Optimal improvement in β-cell function of T2DM patients is seen with 
early, intensive, short-term treatment with insulin vs. metformin or a sulfonylurea. 
Increase in β-cell function helps to improve metabolic control, increase insulin secretion, 
increase acute insulin response to glucose and decrease PI/IRI ratios.  Due to the 
progressive nature of T2DM, this improvement in β-cell function deteriorates gradually 
with time.   
 
Keywords:  Type 2 diabetes mellitus, insulin, metformin, sulfonylurea, beta-cell function 
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THE EFFECT OF INSULIN VS. METFORMIN OR 
SULFONYLUREA TREATMENT ON β-CELL FUNCTION IN 
NEWLY DIAGNOSED TYPE 2 DIABETES PATIENTS 
  
Introduction 
 
 Barely a day goes by without mention in the news of the increasing number of 
patients being diagnosed with Type 2 Diabetes Mellitus (T2DM).  In a recent study 
conducted in China, 44% of newly diagnosed T2DM patients treated with intensive 
insulin therapy went into remission, and normoglycemia was maintained for up to one 
year with diet and exercise.1  Remission was attributed to early intervention with 
intensive glycemic control, reducing glucotoxicity and enabling pancreatic β-cell rest 
and recovery of function.  Most patients with T2DM are treated with diet and lifestyle 
changes first, and then with oral medications.2  Initial treatment of T2DM with insulin 
therapy and the resulting induction of remission was a novel concept.  Further reading 
on this subject matter lead to the development of the clinical question:  What effect 
does insulin treatment have on β-cell function in newly diagnosed T2DM patients? 
Background 
 
 Diabetes mellitus is a progressive, chronic, incurable disease that involves 
either the lack of insulin production in Type 1 diabetes, or insulin resistance in Type 2 
diabetes.3  Insulin is a hormone produced by β-cells of the pancreas, in the islets of 
Langerhans.  The body requires insulin to change sugar, carbohydrates and other food 
into the energy necessary to sustain life.4  Diabetes was first described in1552 BC, by 
an Egyptian physician, Hesy-Ra, as “the passing of too much urine,” but it was not 
named until 1425 AD, when ‘diabete’ first appeared in the Middle English language.  
Diagnosis made by the presence of sugar in urine was established in 1776, by an 
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English physician, Matthew Dobson, and medical treatment was first prescribed by 
John Rollo, a physician in Scotland, in 1797.  Pancreatic islet cells were discovered 
by a German medical student, Paul Langerhans in 1869.  Research by Dr. Frederick 
Banting, lead to the discovery of endogenous insulin in 1921, shortly after which 
insulin was mass produced by Eli Lilly in 1922.  It was not until 1959, that the 
differences between Type 1 and Type 2 diabetes were recognized.5   
 Today, diabetes affects over 23.6 million adults and children in the United 
States (US).  An estimated 5.7 million of these people have the disease and are under 
diagnosed, and the number of individuals with the disease is increasing in epidemic 
proportions: From 1990 to 2005, prevalence rates doubled, and from 2005-2007, the 
number of patients diagnosed with diabetes increased by 13.5%.  In the US, 5-10% of 
patients diagnosed have Type 1 diabetes, treated with daily insulin injections and 
dietary control.3,6 
 Type 2 diabetes is the most common form of this disease, and typically occurs 
in obese adults over the age of 40, however, as the general population becomes more 
obese, this disease is being seen more frequently in children and adolescents.7  This 
disease is characterized by hyperglycemia, caused by insulin resistance, reduced 
insulin secretion and increased hepatic glucose production.8  People with T2DM 
produce insulin, but it does not convert sugar into energy.3,4  Blood glucose and 
insulin levels increase, causing hyperglycemia.7  In response to elevated blood 
glucose, β-cells in the pancreas become overworked and gradually lose the ability to 
function.  Disease progression leads to β-cell deterioration and to reduced secretion of 
insulin.8,9  In later stages of the disease, combination treatment with oral medications 
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and insulin is required to maintain glycemic control.10  Early diagnosis and treatment 
of diabetes is essential to reducing hyperglycemia, slowing the loss of  β-cell 
function, and to reducing the added complications of dyslipidemia, hypertension, 
hypercoagulability and obesity.  Improved glycemic control also helps prevent the 
long term complications of neuropathy, nephropathy and retinopathy.4,7 
 Based on standards established by the American Diabetes Association (ADA), 
diagnosis of T2DM is made when fasting plasma glucose (FPG) levels are 126 mg/dL 
and above.  Fasting plasma glucose levels below 100 mg/dL are considered normal, 
and levels of 100-125 mg/dL indicate impaired glucose tolerance or pre-diabetes.  
Two-hour plasma glucose tolerance testing with levels from 140-199 mg/dL indicate 
pre-diabetes, and a level of 200 mg/dL or above is diagnostic for T2DM.11  New 
recommendations made by a panel of experts to the ADA include using hemoglobin 
A1C levels (HbA1C) over 6.5% to diagnose T2DM in children and adults.12 
 Once a patient is diagnosed with T2DM, treatment typically begins with 
dietary changes, weight loss and exercise.3  Weight loss and exercise are critical 
components of successful treatment.  Numerous chemicals released by adipose cells 
alter insulin receptors in the tissue, contributing to insulin resistance and reduced 
insulin sensitivity.4,7  A loss of 5-10 pounds can significantly reduce the risk of 
diabetes, reverse chemically related changes and, in some patients, induce 
remission.13,14,15  The ultimate goal of diabetes treatment is glycemic control, which is 
defined by the ADA as a HbA1C of  7% or less.11  When glycemic control is not 
achieved with dietary changes and exercise, then monotherapy with an oral 
hypoglycemic agent (OHA), either metformin or a sulfonylurea is started.  A 
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sulfonylurea, such as gliclazide, glibenclamide or glyburide, is recommended for 
initial treatment, however, metformin is more commonly prescribed because it has the 
beneficial side effect of weight loss.  If monotherapy fails, then combination OHA 
therapy with metformin and a sulfonylurea is used.  Doses are adjusted until glycemic 
control is achieved.  Insulin is added as a last resort, after combination therapy with 
maximum doses of OHAs fails to maintain glycemic control.2,14  Progressive 
deterioration of glycemic control and hyperglycemia is characteristic in T2DM 
patients, even with combination therapy using different medication classes.9,10 
 Beta-cell dysfunction is present early in T2DM, long before diagnosis is 
made.  By the time hyperglycemia occurs, β-cell secretory ability has already 
decreased by an estimated 50-75%.9,16  Several mechanisms for causing β-cell 
dysfunction have been proposed.9,17  Elevated glucose and lipid levels may be toxic 
and desensitize β-cells.  Increasing insulin resistance and relative insulin deficiency 
may place a high secretory demand on the β-cell, cause exhaustion and lead to cell 
failure.  Patients with T2DM may have some defect in their islet cells or, β-cell mass 
reduction and increased islet amyloidal buildup may contribute to the decline in 
function.9,17   
Beta-cell function may be evaluated several ways.  One method involves 
measuring plasma levels of proinsulin, the precursor molecule to insulin, which is 
processed by cleaving off the c-peptide chain, forming a mature insulin molecule 
available for use by the body. 9  Individuals with T2DM often have elevated levels of 
proinsulin and proinsulin-to-insulin ratios, which suggest incomplete insulin 
processing and reduced secretory capacity, and serves as a marker for increased β-cell 
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dysfunction.9,18  C-peptide levels are a strong measure of insulin secretion, but do not 
measure insulin action or sensitivity.  Another commonly accepted method for 
measuring β-cell function and estimating insulin sensitivity is the Homeostasis Model 
Assessment (HOMA), which uses fasting plasma glucose, insulin, and c-peptide 
levels for calculations.9,19  HOMA B levels measure the basal rate of insulin 
secretion, while HOMA IR measures insulin resistance.  In healthy individuals, 
insulin and c-peptide levels increase in response to elevated levels of glucose, while 
patients with T2DM will have a delayed or absent response.9  The HOMA B level is 
higher, and HOMA IR level lower in healthy patients as compared to T2DM 
patients.9,19   
Materials and Methods 
A comprehensive literature search was performed using combinations of the 
keywords: Type 2 diabetes,  Type 2 diabetic, NIDDM, insulin, glycemic control, 
beta-cell, β-cell, metformin, sulfonylurea, randomized, c-peptide, HOMA, and 
remission, on Ovid-Medline, CINAHL and PubMed-Medline databases.  Literature 
from 1998 to the present was reviewed by title and abstract.  Relevant articles were 
compiled, analyzed and cross-referenced, using a cited reference search on the Web 
of Science database, for other pertinent literature.  Reference sections from relevant 
articles were also reviewed for literature pertaining to the subject matter.  The 
inclusion criteria were all clinical studies in the English language, published after 
1998 that were a minimum of six months in length and involved: 1) treatment of 
newly diagnosed T2DM patients with insulin monotherapy or with OHAs, metformin 
and/or a sulfonylurea, and 2) evaluation of β-cell function.  Preference was given to 
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randomized studies.  Exclusion criteria were articles published before 1998, non-
English language works, studies less than six months in duration, articles without 
evaluation of β-cell function, studies which combined insulin and oral hypoglycemic 
medications, used oral medications other than metformin or sulfonylurea, or included 
patients which were not newly diagnosed.   
Results 
 A total of five articles comparing insulin treatment with oral hypoglycemic 
medications were published, that included evaluation of β-cell function.  One study 
began treatment with monotherapy, and when that failed, insulin and OHA 
combination therapy was used, and the study was excluded.10  Study criteria for the 
relevant articles are summarized in Table 1.  These articles address the effectiveness 
and remission rates between insulin treatment as compared to oral hypoglycemic 
treatment of patients, and the effect of treatment on β-cell function and metabolic 
control.   
Chandra et al, studied 60 subjects in India, treated with either insulin or 
gliclazide, to compare the effectiveness and remission rate between groups.20  
Patients with a mean of three fasting blood glucose (FBG) levels > 200 mg/dL, were 
included in the study.  Treatment was chosen by the patient and groups were equal in 
size.  All subjects in the study received diabetes education regarding lifestyle 
changes, nutrition and the monitoring of FBG levels, which was reinforced during 
each follow-up visit.  Subjects monitored FBG levels and discontinued treatment 
when levels remained less than 90 mg/dL for at least one week in gliclazide treated 
patients, and when FBG levels remained less than 100 mg/dL for over one week or 
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when hypoglycemia occurred in insulin treated patients.  Fasting plasma glucose 
levels normalized within two to six weeks for both groups.  Subjects in the insulin 
group were treated an average of 3 months before remission was induced.  At six 
months, 3.3% of gliclazide subjects and 80% of insulin subjects were in remission.  
At twelve months, 5% of gliclazide subjects and 62.5% of insulin subjects remained 
in remission.  Post-prandial c-peptide levels evaluating β-cell function were measured 
at baseline and six months.  No other testing was performed to evaluate β-cell 
function.  Treatment was withdrawn 24 hours prior to testing.  C-peptide levels 
increased from 3.2 to 5.8 ng/mL, in the insulin subjects, and levels remained 
unchanged in the gliclazide subjects, from 3.4 to 3.8 ng/mL, with a significant 
difference between groups (p = 0.0003).  C-peptide levels were not measured at 
twelve months.  Hemoglobin A1C levels measured at baseline and six months 
decreased from 10.4 to 6.2% in both groups.  Thirty subjects enrolled in each group, 
all 60 completed six months of follow-up, and 36 completed twelve months of 
follow-up.  Two patients in the insulin group were lost to follow-up at nine months; 
both were in remission at their last visit.20 
  Weng et al, studied 382 subjects in China, treated with insulin, metformin, 
gliclazide, or metformin with gliclazide, to compare the effect of treatment on β-cell 
function and remission rate.1  All subjects had a FPG level of 7.0-16.7 mmol/L (126-
300 mg/dL) and started with 3-7 days of dietary treatment before randomization into 
one of three groups treated with either, a continuous subcutaneous insulin infusion 
pump (CSII), multiple daily insulin injections (MDI) or an oral hypoglycemic agent 
(OHA), metformin and/or gliclazide.  A target glycemic goal established for all 
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subjects was a FBG level less than 110mg/dL, or two hour post-prandial blood-
glucose level less than 144 mg/dL.  Body-mass index was calculated for all subjects, 
and obese patients in the OHA group started treatment with metformin and non-obese 
patients started with gliclazide. Combination OHAs were used if the subject failed to 
attain glycemic control on monotherapy.  Subjects continued treatment for two weeks 
after the glycemic target was met, and at that point, treatment was discontinued and 
the subjects only used diet and exercise for glycemic control.  If glycemic control was 
not reached, the subject was dropped from the study.  Glycemic control was reached 
in 92.1% of all subjects in 7.9 days, 97.1% of CSII subjects in 4.0 days, 95.2% of 
MDI subjects in 5.6 days, and 83.5% of OHA subjects in 9.3 days.  Statistical 
differences were found between OHA and CSII groups (p < 0.0001) and between 
OHA and MDI groups (p = 0.01).  Prior to treatment, all groups had similar β-cell 
function, as measured by acute insulin response to glucose, HOMA B, HOMA IR, 
and proinsulin-to-immunoreactive insulin (PI/IRI) ratios.  Acute insulin response was 
absent in all groups before treatment.  After treatment, acute insulin response and 
HOMA B significantly increased in all subjects (p < 0.0001), while HOMA IR and 
PI/IRI ratios both significantly decreased (p < 0.0001).  There was no statistical 
difference seen in HbA1C levels, measured before and after treatment, and a 
comparable reduction in HbA1C level was seen in all groups.1   
After one year, 42.0% of all subjects who reached glycemic control remained 
in remission, which included 51.1% of the CSII group, 44.9% of the MDI group and 
26.7% of the OHA group.  Remission rate was significantly higher in the insulin 
treated groups than in the OHA treated group (p = 0.0012).  Acute insulin response at 
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one year remained increased in the insulin treated groups and decreased in the OHA 
treated groups, with a significant difference between the CSII and OHA groups  
(p = 0.006), and no difference between MDI and OHA groups (p = 0.097).  Patients 
lost to follow-up, included 23 subjects who did not achieve glycemic control, 7 who 
withdrew from the study due to gastrointestinal side effects from metformin, and 21 
who dropped out of the study due to immigration issues or were lost to follow-up.1   
Alvarsson conducted a four-year study in two parts.21,22  Results for the first 
two years are published in Alvarsson 2003, where 51 subjects in Sweden were 
studied, to determine whether metabolic control and β-cell function improves with 
insulin or glibenclamide treatment.21  The glycemic goal for treatment was a HbA1C 
level < 1% above the normal level, however, “normal level” was never defined.  At 
the time of publication, the ADA standard for a normal HbA1C was < 6.5%.  
Subjects included in the study had FPG levels from 7.0-12.0 mmol/L (126-216 
mg/dL), and were excluded from the study if pharmacologically treated for more than 
six months.  All subjects in the study were screened for T2DM during a 30 day period 
of dietary treatment before randomization to two groups.  Beta-cell function was 
evaluated during treatment and after short-term withdrawal of treatment, and all 
measurements were made at baseline and yearly during the study.  Fasting c-peptide, 
insulin and proinsulin levels were measured during treatment.  Measurements of 
insulin, proinsulin and post-glucagon c-peptide levels were also measured after 
treatment was withdrawn, on two consecutive days, 48 hours before testing on the 
first day, and 72 hours before testing on the second day.  After testing was completed, 
treatment was restarted.  Fasting c-peptide levels were not significantly different 
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between the groups during the study, while post-glucagon c-peptide levels in the 
insulin group increased significantly from baseline at one year (p = 0.03) and from 
one to two years (p < 0.01), and remained unchanged in the glibenclamide group.  A 
significant difference in post-glucagon c-peptide levels between the insulin and the 
glibenclamide group was seen at one year (p = 0.02).  Fasting insulin levels increased 
in the insulin group as compared to the glibenclamide group at one year (p = 0.10), 
and at two years (p = 0.02).  After one year of treatment, HbA1C levels in both 
groups decreased significantly from baseline levels (p < 0.01).  At year two, HbA1C 
levels of the insulin group remained significantly different from baseline (p < 0.005).  
Although the HbA1C level for the glibenclamide group increased at year two, it was 
significantly different from year one (p < 0.01).21   
Alvarsson 2008 follows the 34 Swedish patients remaining in the Alvarsson 
2003 study for two more years.22  Fasting c-peptide levels increased in the 
glibenclamide group and were significantly higher at 30 months than the insulin 
group levels, which decreased during the study (p = 0.003).  Fasting insulin levels 
were unchanged in the glibenclamide group and increased in the insulin group, 
however, there was no significant difference between groups.  Fasting proinsulin-to-
insulin ratios decreased from baseline in both groups during treatment, but remained 
significantly higher in the glibenclamide group than the insulin group for the duration 
of the study (p = 0.04).  Hemoglobin A1C levels for the insulin group decreased at 
one year and remained below 6.5% for the duration of the study, while the HbA1C 
levels for the glibenclamide group increased each year, and were significantly 
different from the insulin group at four years (p = 0.04).22   
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When treatment was withdrawn for testing, fasting insulin levels for all four 
years, proinsulin levels at four years and proinsulin-to-insulin ratios at four years, 
were all higher in the insulin group than the glibenclamide group (p = 0.006,  
p = 0.004 and p = 0.066, respectively).  Post-glucagon c-peptide levels were 
significantly higher in the insulin group than the glibenclamide group at one year  
(p = 0.004), and at two years (p = 0.02).  For a total of all four years, the effect was 
significant (p = 0.018), however, there was no difference between groups after three 
years.  A total of 51 subjects began the study and 34 completed all four years.  
Patients lost to follow-up included 1 subject who died in surgery, 1 died of cancer, 9 
left for personal reasons, 4 glibenclamide subjects required insulin treatment, and 2 
subjects developed insulin antibodies and were excluded from the study.22  A 
summary of study results is listed in Table 2. 
Discussion 
The primary goal of this study was to identify evidence from current medical 
literature on the effect of insulin treatment on β-cell function in newly diagnosed 
T2DM patients, as compared to metformin and/or sulfonylurea treatment.  
Considerable differences existed between study groups.  Criteria used for diagnosing 
T2DM in all of the studies were consistent with ADA standards, however Chandra 
used three separate screenings prior to diagnosing T2DM, while all other groups  
screened subjects once.  Relevant studies were conducted in India, China and 
Sweden, all of which have wide variations in diet.  Treatment consisted of intensive 
glycemic control in Weng, and conventional treatment in Chandra, Alvarsson 2003 
and Alvarsson 2008.  Chandra included comprehensive diabetes education reinforced 
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at each visit, while Weng began the study with a 3-7 day period of dietary changes, 
and encouraged subjects to maintain glycemic control with diet and exercise.  
Alvarsson 2003 and Alvarsson 2008 evaluated subjects for T2DM during a one 
month period of dietary treatment, but make no mention of treatment including diet or 
exercise, both of which are important factors in weight loss and glycemic control.  
Studies by Chandra and Weng evaluated remission and β-cell function, while 
the study by Alvarsson 2003 and Alvarsson 2008 evaluated β-cell function and 
metabolic control.  Remission was defined as euglycemia and normoglycemia by 
Chandra and Weng, and target glycemic goals of FPG < 110 mg/dL were set, which 
still falls within the pre-diabetes range, based on ADA standards.  Alvarsson 2003 
and Alvarsson 2008 treated subjects to obtain a HbA1C level < 1% above normal, 
which was likely 6.5%.  Population size was very small in Chandra, Alvarsson 2003 
and Alvarsson 2008, with 60, 51, and 34 subjects, respectively.  With 382 subjects, 
the population in Weng was relatively large, and may be a more accurate 
representation of the T2DM population.  Chandra reported findings at 6 months for 
100% of study participants, and at 12 months for over 50% of participants.  Weng 
reported findings from 1 year of study, Alvarsson 2003 from 2 years, and Alvarsson 
2008 from 4 years.  The effect of treatment was seen in all studies.  
Chandra measured post-prandial c-peptide levels at baseline and six months, 
and testing was performed after subjects withheld treatment for 24 hours.  C-peptide 
levels increased significantly in the insulin group, while little variance was seen in the 
gliclazide group.  Elevated c-peptide levels indicate increased insulin secretion, but 
no other testing was done in this study to evaluate insulin action or resistance, which 
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is a limitation of this study.  Hemoglobin A1C levels decreased from 10.4 to 6.2% in 
both groups, which meets the criteria for glycemic control established by the ADA.  
At 6 months, 80% of insulin subjects and 3.3% of gliclazide subjects were in 
remission, and at 12 months, 62.5% of the insulin subjects and 5% of the gliclazide 
subjects were in remission.  These findings suggest that β-cell function improves with 
insulin treatment, indicated by increased insulin secretion, metabolic control and 
induced remission in most subjects.  They also suggest that T2DM remission may be 
short-term, with fewer subjects remaining in remission at 12 months.  This decrease 
in remission may relative, and due in part to the large number of patients lost after 6 
months of treatment.  Unchanged c-peptide levels in the gliclazide group suggest that, 
although metabolic control is maintained, insulin secretion and β-cell function are 
unaffected by this treatment.   
The Chandra study was unique in that it included comprehensive diabetes 
education, which may be a contributing factor to the dramatically improved HbA1C 
levels in both groups and to the high remission rates in the insulin group.  It does not, 
however, explain the lower remission rate seen in the gliclazide group, which 
received the same education.  Because insulin works by a different mechanism of 
action than gliclazide, pharmacological differences may account for variance in 
remission rate.  Another unique difference in this study is that the subjects chose their 
treatment, which may have contributed to increased compliance with the study 
requirements. 
Weng thoroughly evaluated β-cell function by measuring HOMA B, HOMA 
IR, acute insulin response to glucose, and PI/IRI ratios, before and after 2-5 weeks of 
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intensive treatment with CSII, MDI or OHAs.  HOMA B and acute insulin response 
increased in all groups, indicating increased insulin secretion, while HOMA IR and 
PI/IRI ratios decreased, indicating decreased insulin resistance and increased insulin 
secretory capacity.  Acute insulin response levels remained elevated in the CSII and 
MDI groups after 1 year, and decreased significantly in the OHA group, which 
suggests that long-term improvement of β-cell function may be obtained with insulin 
treatment.  HbA1C levels decreased in all groups from baseline, however, levels after 
2-5 weeks of treatment ranged from 7.9-8.0%, which exceeded the ADA standard for 
glycemic control of < 7%.  At one year, 51.1% of the CSII group, 44.9% of the MDI 
group and 26.7% of the OHA group remained in remission, which is considerably 
lower than the remission rates for insulin treatment seen in Chandra.  Duration of 
treatment in these two groups varied considerably.  After meeting glycemic targets, 
subjects in the Weng study were treated for an average of 2-5 weeks, while in 
Chandra, insulin subjects were treated an average of 3 months.  These findings 
suggest that intensive insulin treatment for greater than 5 weeks may increase 
remission rates and decrease HbA1C levels.  One unique part of this study was the 
use of insulin pumps by the CSII group.  An insulin pump closely mimics pancreatic 
function with a sustained infusion of basal insulin into the body 24 hours a day.  
Although the greatest improvement of β-cell function was seen in CSII group, the use 
of an insulin pump for short-term insulin therapy is neither cost-effective or practical.   
Alvarsson 2003 evaluated the effect of insulin or glibenclamide treatment on 
β-cell function and metabolic control by measuring fasting insulin, proinsulin, and  
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c-peptide levels, and post-glucagon c-peptide levels.  Although this study included 
subjects who had received some pharmacological treatment, all subjects had FPG 
levels of 126-216 mg/dL while on dietary treatment alone.  This pre-treatment of 
subjects in Alvarsson may account for the lower baseline HbA1C levels from 6.8-
7.3%, as compared to Chandra, with HbA1C levels of 10.4%, and Weng, with 
HbA1C levels from 9.5-9.8%.  At one year, HbA1C levels had decreased in both 
groups, and at two years, HbA1C levels increased in the glibenclamide group and 
remained decreased in the insulin group, suggesting better long-term metabolic 
control with insulin treatment.  During the first two years of the study, post-glucagon 
c-peptide levels and fasting insulin levels increased in the insulin group, with 
significant differences from the glibenclamide group.  These findings are consistent 
with Chandra and Weng, and suggest that increased insulin secretion improves with 
insulin treatment, which relates to improved β-cell function. 
In Alvarsson 2008, fasting c-peptide levels and proinsulin-to-insulin ratios 
were consistently higher in the glibenclamide group than the insulin group, and 
fasting insulin levels began to decrease in the glibenclamide group suggesting a 
deterioration of β-cell function.  During the short-term withdrawal of treatment, post-
glucagon c-peptide levels decreased in both groups, with a greater decline seen in the 
glibenclamide group.  At four years, proinsulin and proinsulin-to-insulin levels 
increased in the insulin group, HbA1C levels remained below 6.5% in the insulin 
group, and were approximately 7.0% in the glibenclamide group.  As in Chandra, 
where remission rates were high early in the study and declined with time, Alvarsson 
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2008 further illustrates the gradual decline of function over time, with the greatest 
decline seen in OHA treated subjects, even while maintaining metabolic control. 
The primary limitation to this study was the small number of studies 
pertaining to the subject matter.  Because T2DM requires combination therapy as the 
disease progresses, it is difficult to find studies relying on monotherapy.  Variability 
between studies was also a limitation, Chandra and Alvarsson evaluated insulin 
treatment vs. a sulfonylurea, and Weng evaluated two types of insulin treatment vs. 
metformin, a sulfonylurea, and metformin combined with a sulfonylurea.  Doses 
between groups, glycemic targets, duration of treatment, inclusion criteria of study 
subjects and evaluation of β-cell function varied as well.  Additional study is needed 
to fully evaluate the effect of insulin treatment on β-cell function in T2DM patients. 
Recommendations 
There is no cure for T2DM, and although the initial treatment for this 
progressive disease does not currently include insulin, a short course of treatment 
may provide the long-term benefits of improved β-cell function, and may induce 
remission in some patients.  When the conventional step-wise approach to treatment 
is followed, it may be 10-15 years before insulin is used in a T2DM patient.  Using 
insulin sooner will improve metabolic control and reduce the complications of 
nephropathy, neuropathy and retinopathy that occur with poor glycemic control.13  
Insulin treatment is individualized, varied and based on the needs of the patient.23  
Starting a patient on insulin involves time and training, which places a heavy burden 
on the provider and is often a barrier to beginning treatment.24  There is also the 
added risk of hypoglycemic events with insulin use, which rarely occur with OHAs.25  
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Making the transition from insulin to OHAs is less difficult, as oral medication may 
be taken while tapering off insulin.  Regardless of the treatment involved, T2DM is a 
disease which requires self-management by the patient.  An integral part of treatment 
for all newly diagnosed patients should include comprehensive education regarding 
lifestyle change, diet, exercise and weight loss.  Results from the Chandra study 
support this recommendation and suggest that education with reinforcement may 
correlate with better glycemic control.20 
Conclusion 
Based on this literature review, it can be concluded that optimal improvement 
in β-cell function of T2DM patients is seen when early, intensive, short-term 
treatment with insulin is combined with comprehensive diabetes education regarding 
lifestyle changes, nutrition and blood-glucose monitoring.  Increase in β-cell function 
will improve metabolic control, increase insulin secretion, increase acute insulin 
response and decrease PI/IRI ratios.  Due to the progressive nature of T2DM 
however, this improvement in β-cell function will deteriorate gradually with time.  
Additional topics for future study may include the impact of diabetes education on 
maintaining glycemic control, and the treatment of existing T2DM subjects with 
intensive insulin therapy to evaluate β-cell function, or to evaluate whether insulin 
treatment will resensitize subjects to lower doses of OHAs. 
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Author/ 
Year 
Published 
Study Type Study 
Time 
Pop
Size 
Patient 
Ages 
Treatments 
Studied 
Type 2 Diabetes 
Diagnosis Criteria 
Target Glycemic 
Goal 
Beta-Cell 
Function Criteria 
Time of  
Measurements 
Remission Criteria 
Chandra 
2008 
Non-
Randomized 
 
1 yr 60 44 yrs 
(+ 10) 
Insulin injections 
Gliclazide 
Mean FPG > 200 mg/dL  
3 screenings 
FPG < 110 mg/dL C-peptide 
 
Baseline 
6 mos 
Euglycemia 
At 1month  
post-treatment 
 
Weng 
2008 
Randomized 
Multi-center 
1 yr 382 25-70 yrs Insulin pump 
Insulin injections 
Metformin 
Gliclazide 
 
FPG 7.0 – 16.7 mmol/L 
(126-300 mg/dL) 
1 screening 
FPG < 6.1 mmol/L 
( 110 mg/dL) 
HOMA B 
HOMA IR 
Insulin response 
PI/IRI ratio 
Baseline 
Normoglycemia 
1 year 
Normoglycemia 
 At 1 yr 
post-treatment 
Alvarsson 
2003 
Randomized 
Multi-center 
2 yrs 51 35-70 yrs Insulin injections 
Glibenclamide 
FPG 7.0 – 12.0 mmol/L 
(126-216 mg/dL) 
1 screening 
 
HbA1C < 1% 
Over normal 
C-peptide 
Proinsulin 
Insulin 
Baseline 
1 year 
2 years 
Not assessed 
Alvarsson 
2008 
Randomized 
Multi-center 
4 yrs 34 35-70 yrs Insulin injections 
Glibenclamide 
FPG 7.0 – 12.0 mmol/L 
(126-216 mg/dL) 
1 screening 
 
HbA1C < 1% 
Over normal 
C-peptide 
Proinsulin 
Insulin 
PI/IRI ratio 
 
Baseline 
Yearly 
Not assessed 
 
Table 1.  Summary of study criteria for reviewed articles.  FPG = Fasting plasma glucose, Pop = population. 
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Study  Patient 
Counseling 
Time to  
Normal FPG 
Percent 
Remission 
6 mos 
Percent  
Remission 
12 mos 
HbA1C 
Baseline 
HbA1C 
Post-Tx* 
C-peptide 
Baseline 
C-peptide* 
 
PI/IRI 
Ratio 
Baseline 
PI/IRI * 
Ratio 
Post-Tx 
AIR 
Baseline 
 
AIR 
Post-Tx 
 
AIR 
12 mos 
 
Chandra 
2008 
Education 
Diet 
Exercise 
Insulin       2-6 wks 80%  62.5 %  
 
10.4% 
 
6.2% 3.2 ng/L 5.8 ng/L      
Gliclazide  2-6 wks  3.3% 5% 10.4% 6.2% 3.4 ng/L 3.8 ng/L      
Weng 
2008 
Diet 
Exercise 
CSII         4.0 days  51.1% 9.8% 8.0%   23.8% 12.1% -62 
pmol/L/min 
889 
pmol/L/min 
809 
pmol/L/min 
 
MDI         5.6 days   44.9% 9.7% 8.0%   26.5% 16.8% -7 
pmol/L/min 
 
793 
pmol/L/min 
729 
pmol/L/min 
 
OHA        9.3 days   26.7%  9.5% 7.9%   28.4% 21.2% -95 
pmol/L/min 
 
736 
pmol/L/min 
335 
pmol/L/min 
 
Alvarsson 
2003 
N/A Insulin             N/A     7.3% ~ 6.0% 
 
       
Glibenclamide N/A     6.8%  ~ 6.4%  
 
       
Alvarsson 
2008 
N/A Insulin             N/A     7.3%  ~ 6.4% 
 
       
Glibenclamide N/A     6.9%  ~ 7.0% 
 
       
 
Table 2.  Summary of study results for reviewed articles.  Numerical data was not provided by Alvarsson 2003  
or Alvarsson 2008. *Measurements: Chandra-6 months, Weng-2 days post-normoglycemia, Alvarsson 2003-2 yrs,  
Alvarsson 2008-4 yrs. AIR = Acute insulin response, PI/IRI = proinsulin-to-insulin ratio, Tx = treatment.  
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